Windlas Biotech Ltd. (WINDLAS) — Tipsheet

Windlas Biotech misses Plant 6 timeline as regulatory hit cuts revenue

Tipsheet Editorial — Fri, 22 May 2026 13:54:23 GMT

Regulatory action wiped out the company's codeine syrup business, while geopolitical tension and solvent costs weigh on margins.

What’s new

Plant 6 commercialization is pushed to H1 FY27 despite mechanical completion.
The codeine syrup business loss creates a ₹50-60 cr revenue hole.
Exports grew 40% annually to ₹46 cr, with Q4 growth hitting 67%.

Why it matters

The delay at Plant 6, paired with the loss of a major product line, forces the company to find new revenue sources while fighting margin decay. Rising API costs leave little room for error as the firm works to replace its lost liquid product portfolio.

What we’re watching

The speed of replacement for the lost syrup revenue.
Margin recovery against the current cost-inflationary trend.
The start date for commercial production at Plant 6.

The full read

Windlas Biotech faces two distinct headwinds. First, the regulatory loss of its codeine syrup business removed ₹50-60 crore in annual revenue, leaving the firm to source liquid product alternatives. Second, the Plant 6 expansion will not see commercial production until the first half of the next financial year, missing earlier expectations. Margin pressure is also rising as the firm pays more for solvents and API supplies hit by West Asia geopolitical tension. Exports provided some relief with 40% annual growth to ₹46 crore, aided by a 67% jump in the final quarter. Management sees a theoretical revenue ceiling of ₹1,000 crore and 10-15% efficiency upside, but the immediate test is filling the revenue gap while navigating a tightening cost environment.

Primary source: BSE · NSE

Windlas Biotech’s ₹904 Cr revenue: record, but already priced in.

Tipsheet Editorial — Thu, 21 May 2026 17:39:07 GMT

Q4/FY26 results show 19% revenue growth and 31% PAT growth, but these numbers were disclosed in earlier filings. Real story: 13th consecutive record quarter and Plant-6 on track.

What’s new

Revenue grew 19% YoY to ₹904 Cr, crossing ₹900 Cr for the first time.
Adjusted PAT up 31%; 13th straight quarter of record revenue.
Plant-6 mechanical completion noted; results widely anticipated.

Why it matters

Windlas delivered a solid year with margin expansion and capital efficiency. But these numbers were already expected after the annual results and buyback filings. The market's reaction is likely muted; the focus now shifts to how Plant-6 capacity converts into FY27 growth.

What we’re watching

Plant-6 ramp-up and its impact on FY27 margins.
Whether the company can sustain double-digit growth as the base expands.
Any update on order book or new customer wins in the concall.

The full read

Windlas Biotech's FY26 results are impressive on paper: 19% revenue growth, 31% PAT growth, and a first-time cross of ₹900 Cr in annual revenue. The company also notched its 13th consecutive quarter of record revenue. However, these figures were already disclosed in the annual results and buyback filings, making today's press release confirmatory rather than revelatory. Management's commentary on operational discipline and Plant-6 mechanical completion is positive but not new. For investors, the open question is FY27: can capacity expansion drive incremental growth without margin compression? The market had already priced in FY26; the forward story is what matters now.

Primary source: BSE · NSE

Windlas lifts dividend to ₹6.30 as profit rises 9% in FY26

Tipsheet Editorial — Thu, 21 May 2026 16:54:00 GMT

Revenue grew 19% to ₹9,041M; profit touched ₹664M. Both numbers were in line with expectations.

What’s new

Dividend raised to ₹6.30 vs ₹5 last year.
Revenue up 19% YoY, net profit up 9%.
Results were widely anticipated; no surprises.

Why it matters

The dividend increase signals confidence, but the results were already priced in after prior guidance and buyback. For a micro-cap pharma, steady execution is expected; this filing doesn't alter the thesis.

What we’re watching

Next quarter's revenue trajectory.
Any signal on capex or new product launches.
Whether the buyback completion affects float.

The full read

Windlas posted predictable numbers for FY26—₹9,041M revenue, ₹664M profit—in line with guided expectations. The dividend bump to ₹6.30 is a small positive but not a surprise. With no deviation from anticipated performance, the filing confirms the existing narrative without adding trading torque.

Primary source: BSE · NSE

Windlas Biotech meets FY26 estimates; dividend raised to ₹6.30

Tipsheet Editorial — Thu, 21 May 2026 16:34:56 GMT

Revenue grew 19% to ₹9,041 mn, net profit rose 9% to ₹664 mn. Results were widely anticipated with no material surprises.

What’s new

FY26 revenue up 19% YoY to ₹9,041 mn
Net profit rose 9% YoY to ₹664 mn
Dividend hiked from ₹5 to ₹6.30 per share

Why it matters

Steady operational performance but fully expected after prior guidance and buyback completion. No new tradeable insights for the micro-cap pharma stock.

What we’re watching

Any change in growth trajectory in FY27
Sustainability of margin trends

The full read

Windlas Biotech's audited FY26 results confirm the trajectory already implied by its buyback and prior commentary. Revenue hit ₹9,041 million, up 19%, and net profit rose 9% to ₹664 million. The dividend increase to ₹6.30 per share (126% face value) is modest but welcome. The numbers are clean but routine — no surprises, no guidance deviation. For a micro-cap pharma that has already communicated its outlook, this annual filing offers nothing to alter the consensus view.

Primary source: BSE · NSE